U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085767) titled 'Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer' on July 08.
Brief Summary: This phase 3 clinical trial compares the efficacy and safety of palazestrant with ribociclib to letrozole and ribociclib in women and men who have not received prior systemic anti-cancer treatment for advanced breast cancer.
Study Start Date: Oct. 31, 2025
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Locally Advanced Breast Cancer
Metastatic Breast Cancer
ER Positive Breast Cancer
HER2 Negative Breast Carcinoma
Intervention:
DRUG: Palazestrant
Participants will be treated with palazes...